Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is a multicenter trial performed in Japan, consisting of a comparative study
period and a continuous administration period.
Effect of 0.15% UF-021 eye drops on improvement in central retinal sensitivity with HFA will
be verified in 52 weeks comparative study period by a placebo-controlled, double-masked study
in patients with retinitis pigmentosa.
The safety of same eye drops will also be examined in 52 weeks continuous administration
period, in all the patients who completed the comparative study period.